Mylan N.V. has received regulatory clearance for pretomanid in India, improving the prospects of expanded access to the new treatment for drug-resistant tuberculosis, amid disturbing signals that the world’s most deadly infection may rebound sharply while healthcare systems are currently burdened with treating COVID-19.
Pretomanid, developed by the non-profit organization TB Alliance, has been given the go-ahead by the Drugs Controller General of India...







